Leuko Revenue and Competitors

Claim your profile

Boston, MA USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Leuko's estimated annual revenue is currently $4M per year.(i)
  • Leuko's estimated revenue per employee is $286,857

Employee Data

  • Leuko has 14 Employees.(i)
  • Leuko grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.8M370%N/AN/A
#2
$3M230%N/AN/A
#3
$4M148%N/AN/A
#4
$4.5M14-12%N/AN/A
#5
$5630M69534%$450MN/A
#6
$4M148%N/AN/A
#7
$6.8M4419%$29.6MN/A
#8
$12.6M4926%N/AN/A
#9
$2M138%$44MN/A
#10
$54.6M20716%N/AN/A
Add Company

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

keywords:N/A

N/A

Total Funding

14

Number of Employees

$4M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Leuko News

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-04-20 - Judges: Joint winners at INVEST Pitch Perfect's RPM track ...

Another company Leuko, based in Spain, is targeting cancer patients with a device that claims to be the first device for non-invasive white...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

2022-03-22 - Trastuzumab deruxtecan shows 'terrific activity' in second line ...

... GlaxoSmithKline, Guardant Health, Leuko, Lilly, Medica Scientia Innovation Research, Menarini, Merck Sharp & Dohme, Nektar Therapeutics,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M14-33%$250.5M
#2
$2M14-22%N/A
#3
$1.5M140%$78M
#4
$1M140%$50M
#5
$2.3M14N/AN/A